JAMES LUST: Open Payments
NPI 1831116466 · DOVER, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,653 in 120 payments from 32 companies in 2025. Trend: 2023 $7,599 · 2024 $8,376 · 2025 $2,653
Food & beverage: $2,653
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $382 |
| Lundbeck LLC | 8 | $182 |
| Biogen, Inc. | 8 | $175 |
| UCB, Inc. | 6 | $161 |
| E.R. Squibb & Sons, L.L.C. | 1 | $158 |
| Novartis Pharmaceuticals Corporation | 10 | $149 |
| Otsuka America Pharmaceutical, Inc. | 2 | $138 |
| PFIZER INC. | 17 | $136 |
| Lilly USA, LLC | 1 | $124 |
| Amneal Pharmaceuticals LLC | 5 | $122 |
Products named: ZEPOSIA, REXULTI, VYEPTI, KESIMPTA, BOTOX, NURTEC ODT, KISUNLA, QULIPTA.
Industry payments across DE — which companies pay providers there.
